Novel Immune Checkpoint Inhibitors, Bispecific Antibodies Become Clinical Mainstays in Melanoma Nursing
Source: Onc Nursing News, June 2023
What are the implications of new approvals for oncology nurses specializing in melanoma?
In the past year, relatlimab combined with nivolumab (Opdualag) entered the clinical landscape for the treatment of patients with advanced melanoma.1 Tebentafusp (Kimmtrak), a bispecific antibody, also gained approval from the FDA for patients with uveal melanomas.2 What are the implications of these approvals for oncology nurses specializing in melanoma?
In an interview with Oncology Nursing News, Krista M. Rubin, MS, FNP-BC, RN, a nurse practitioner with the Center for Melanoma at Mass General Cancer Center in Boston, reflected on her experience integrating these agents into clinical practice and discussed what oncology nurses working in this setting need to know. Rubin is chair of the Melanoma Nursing Initiative and has been specializing in melanoma for the past 25 years.